Trials / Recruiting
RecruitingNCT05282108
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia; a Multicenter, Observational Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 240 (estimated)
- Sponsor
- Hikma Pharmaceuticals LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Detailed description
This is an observational, prospective, cohort study design, where no visits or intervention(s) additional to the daily practice will be performed. In the study site, two cohorts will be identified among eligible patients, followed up, and assessed for a total of 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carcemia | Generic Imatinib |
| DRUG | Glivec | Imatinib |
Timeline
- Start date
- 2022-07-20
- Primary completion
- 2026-08-01
- Completion
- 2026-11-01
- First posted
- 2022-03-16
- Last updated
- 2025-03-26
Locations
4 sites across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05282108. Inclusion in this directory is not an endorsement.